Dermatology Market

Dermatology is a $15 billion market. It ranks 10th among other indication categories in terms of dollar sales and represents 5% of total pharmaceutical Rx sales. There is a wide disparity, however, between these sales figures and current drug development activities: only 1-2% of all development activities are for dermatological conditions. Furthermore, current pipeline activity is mainly limited to psoriasis and anti-infectives.

Despite large patient populations with significant unmet needs, comparatively few new dermatology products have come to market in recent years. The important drug classes currently used in dermatology, such as steroids and retinoids, generally represent old products that have been on the market for a long time. Generics dominate the market, and many important branded products will lose patent protection in the near term. This lack of innovation has resulted in anemic sales growth with a cumulative annual growth rate of only 3% in recent years, dermatology sales growth is far below the industry average of 9%.

SWITCH BIOTECH is currently in the early stages of research and development of several products that it may potentially submit to the FDA for regulatory approval. Our therapeutic efforts are focused on therapies for Psoriasis, Acne Vulgaris, Actinic Keratoses, Atopic Dermatitis, Cutaneous Ulcers and Onychomycosis (nail fungus).  Additionally we are investigating other compounds for the treatment of conditions outside of dermatology.

We are investigating traditional pharmaceutical compounds and biotechnology approaches to treat diseases of the skin. Our R&D efforts are derived from in-house sources and potential licensing agreements with research and development partners worldwide.